Dean Rudge

Two more generics manufacturers have reached agreements with 50 US attorneys general settling claims that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.

A significant divestment in the works, complex generic launches, a mammoth antitrust fine in Europe – Teva's Q3 was busy and bustling, led by strong, double-digit top-line growth and a further rise in guidance for 2024.

Coherus BioSciences will have to weather the storm of supply interruptions for its sole biosimilar product, Udenyca, in the final quarter of 2024.

Buoyed by the success of its long-acting risperidone injectable, Teva is continuing to feel upbeat about the potential for its olanzapine LAI candidate, ahead of a full study safety readout anticipated in the first half of 2025.

Sandoz has ticked off a pair of corporate milestones, including the opening of a new UK device development center which will serve as a global hub for developing advanced delivery devices supporting the firm's extensive pipeline.

Viatris provided several updates for its launch plans in 2025 during the company's third-quarter earnings call.

Aurobindo is looking to finally put a key manufacturing disruption behind it in Europe, enabling the firm to gain traction for some of its early biosimilar filings.

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

Dr Reddy's Laboratories has spoken at length about its ability to make most of its GLP-1 APIs and formulations in-house, as it looks to be a ‘day one' player for opportunities including semaglutide.

Regeneron has taken a further swipe at Amgen after the biosimilars sponsor surprised the market by launching the first US rival to Eylea at-risk last month.